Beneficial effect of interleukin 1 inhibition with anakinra in adult-onset Still's disease: an open, randomized, multicenter study

Key Findings

• ●Anakinra induced greater remission rates vs DMARDs (7/12 vs 5/10 at 8 weeks)
• ●Anakinra significantly improved physical health (SF-36, p<0.011)

Referenced in (1 disease)